Welcome to BioSeeker Group!

Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline

Additional Information

Published Date Sep 7, 2010
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 1227
PDF Fact Sheet View Fact Sheet for the report Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$2,450.00

Quick Overview

This report comprises defined and up to date development strategies for 239 angiogenesis affecting drugs in oncology within the portfolio of 148 corporate investigators, from Ceased to Marketed. The report extensively analyses their 174 identified drug targets, organized into 167 drug target strategies, and assesses them in 64 different cancer indications.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline.

    To find out more about Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report comprises defined and up to date development strategies for 239 angiogenesis affecting drugs in oncology within the portfolio of 148 corporate investigators, from Ceased to Marketed. The report extensively analyses their 174 identified drug targets, organized into 167 drug target strategies, and assesses them in 64 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any angiogenesis approach for the treatment of cancer to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights™ 4
2.1 Cancer Focus Areas 4
2.2 Subscribe Today and Start Saving 5
2.2.1 Type of License 5
2.3 BioSeeker Group’s Oncology Team 5
3 Methodology 6
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 6
4 Table of Contents 8
4.1 List of Figures 20
4.2 List of Tables 20
5 Introduction 35
5.1 The Scope of this Report 35
5.2 Definitions 38
5.3 Abbreviations 38
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 39
6.1 Drug Repositioning in Oncology 39
6.2 Introduction to Targets of Angiogenesis in Oncology 40
6.2.1 Calcium Ion Binding Targets 43
6.2.2 Carboxy-lyase Activity Targets 44
6.2.3 Catalytic Activity Targets 45
6.2.4 Cell Adhesion Molecule Activity Targets 50
6.2.5 Chaperone Activity Targets 56
6.2.6 Chemokine Activity Targets 60
6.2.7 Cofactor Binding Targets 61
6.2.8 Cysteine-type Peptidase Activity Targets 63
6.2.9 Cytokine Activity Targets 66
6.2.10 Cytoskeletal Protein Binding Targets 70
6.2.11 DNA topoisomerase Activity Targets 71
6.2.12 DNA-directed DNA Polymerase Activity Targets 73
6.2.13 Extracellular Matrix Structural Constituent Targets 74
6.2.14 G-protein Coupled Receptor Activity Targets 79
6.2.15 Growth Factor Activity Targets 84
6.2.16 GTPase Activity Targets 94
6.2.17 Hormone Activity Targets 97
6.2.18 Hydrolase Activity Targets 98
6.2.19 Kinase Activity Targets 99
6.2.20 Kinase Binding Targets 101
6.2.21 Lipid Kinase Activity Targets 102
6.2.22 Metallopeptidase Activity Targets 108
6.2.23 Motor Activity Targets 120
6.2.24 Oxidoreductase Activity Targets 121
6.2.25 Peptidase Activity Targets 123
6.2.26 Phosphoric Diester Hydrolase Activity Targets 139
6.2.27 Protease Inhibitor Activity Targets 141
6.2.28 Protein Binding Targets 145
6.2.29 Protein Serine/Threonine Kinase activity Targets 148
6.2.30 Protein-tyrosine Kinase Activity Targets 175
6.2.31 Receptor Activity Targets 185
6.2.32 Receptor Binding Targets 206
6.2.33 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 211
6.2.34 RNA Binding Targets 213
6.2.35 Serine-type Peptidase Activity Targets 214
6.2.36 Structural Constituent of Cytoskeleton Targets 218
6.2.37 Superoxide Dismutase Activity Targets 219
6.2.38 Transcription Factor Activity Targets 221
6.2.39 Transcription Regulator Activity Targets 230
6.2.40 Transferase Activity Targets 237
6.2.41 Translation Regulator Activity Targets 239
6.2.42 Transmembrane Receptor Activity Targets 244
6.2.43 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 246
6.2.44 Transporter Activity Targets 287
6.2.45 Ubiquitin-specific Protease Activity Targets 291
6.2.46 Voltage-gated Ion Channel Activity Targets 292
6.3 The Cancer Genome Project and Targets of Cancer Drugs Affecting Angiogenesis 293
6.3.1 Targets of Angiogenesis Affecting Drugs in Oncology Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 293
6.4 Structure-based Drug Design in Cancer Angiogenesis Therapeutics is Stimulated by Available Structure Data on Biological Targets 298
6.5 Target-Target Interactions among Identified Targets of Angiogenesis Affecting Drugs in Oncology 302
6.6 The Drug-Target Interactome 307
6.7 Protein Expression Levels of Identified Targets of Angiogenesis Affecting Cancer Drugs 312
6.8 Pathway Assessment of Angiogenesis Affecting Targets in Oncology 316
6.8.1 Tools for Analysis of Cancer Pathways 317
6.8.2 Pathway Assessment 318
7 Emerging New Products to Established Ones: Drug Target Strategies of Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development 367
7.1 Drug Target Strategies of Terminated Cancer Drugs Affecting Angiogenesis 369
7.2 Registered to Marketed: New and Unique Drug Target Strategies of Cancer Drugs Affecting Angiogenesis 374
7.3 Phase III Clinical Development: New and Unique Drug Target Strategies of Cancer Drugs Affecting Angiogenesis 376
7.4 Phase II Clinical Development: New and Unique Drug Target Strategies of Cancer Drugs Affecting Angiogenesis 380
7.5 Phase I Clinical Development: New and Unique Drug Target Strategies of Cancer Drugs Affecting Angiogenesis 388
7.6 Preclinical Development: New and Unique Drug Target Strategies of Cancer Drugs Affecting Angiogenesis 397
7.7 No Development Data: New and Unique Drug Target Strategies of Cancer Drugs Affecting Angiogenesis 401
7.8 Development Profiles of All Cancer Drugs Affecting Angiogenesis 404
7.9 The Competition Through Close Mechanistic Approximation of Cancer Drugs Affecting Angiogenesis 427
8 Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs Affecting Angiogenesis by Compound Strategy 438
8.1 Small Molecules 440
8.1.1 Background 440
8.1.2 Target Strategies of Small Molecule Drugs 441
8.2 Peptide/Protein Drugs 458
8.2.1 Background 458
8.2.2 Target Strategies of Peptide and Protein Drugs 459
8.3 Antibodies and Antibody-like Structures 465
8.3.1 Background 465
8.3.2 Target Strategies of Antibody Drugs 465
8.4 Nucleic Acid Therapies 469
8.4.1 Background 469
8.4.2 Target Strategies of Nucleic Acid Drugs 470
8.5 Gene Therapy 472
8.5.1 Background 472
8.5.2 Target Strategies of Gene Therapy Drugs 472
8.6 Drug Delivery and Nanotechnology 475
8.6.1 Background 475
8.6.2 Target Strategies of Reformulated Drugs 475
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 478
9 Selecting Cancer Indications for Angiogenesis Affecting Drugs in Oncology 486
9.1 Acute Lymphocytic Leukemia 489
9.2 Acute Myelogenous Leukemia 490
9.3 Adrenal Cancer 493
9.4 B-cell Lymphoma 495
9.5 Basal Cell Cancer 496
9.6 Biliary Cancer 497
9.7 Bladder Cancer 498
9.8 Bone Cancer 501
9.9 Brain Cancer 502
9.10 Breast Cancer 506
9.11 Cancer (general) 515
9.12 Cancer Diagnosis 516
9.13 Carcinoid 517
9.14 Cervical Cancer 519
9.15 Chemotherapy-induced Alopecia 520
9.16 Chemotherapy-induced Infection 520
9.17 Chronic Lymphocytic Leukemia 521
9.18 Chronic Myelogenous Leukemia 522
9.19 CNS Cancer 524
9.20 Colorectal Cancer 524
9.21 Endometrial Cancer 534
9.22 Fallopian Tube Cancer 536
9.23 Fibro Sarcoma 538
9.24 Gastrointestinal Cancer (general) 539
9.25 Gastrointestinal Stomach Cancer 542
9.26 Gastrointestinal Stromal Cancer 545
9.27 Head and Neck Cancer 547
9.28 Hodgkin’s Lymphoma 551
9.29 Kaposi’s Sarcoma 551
9.30 Leiomyo Sarcoma 552
9.31 Leukemia (general) 553
9.32 Lipo Sarcoma 555
9.33 Liver Cancer 556
9.34 Lung Cancer (general) 561
9.35 Lymphoma (general) 563
9.36 Mast Cell Leukemia 565
9.37 Melanoma 566
9.38 Mesothelioma 571
9.39 Myelodysplastic Syndrome 573
9.40 Myeloma 575
9.41 Nasopharyngeal Cancer 578
9.42 Neuroendocrine Cancer (general) 579
9.43 Neuroendocrine Cancer (pancreatic) 580
9.44 Non-Hodgkin’s Lymphoma 582
9.45 Non-Small Cell Lung Cancer 584
9.46 Oesophageal Cancer 592
9.47 Oral Cancer 594
9.48 Osteo Sarcoma 594
9.49 Ovarian Cancer 595
9.50 Pancreatic Cancer 600
9.51 Peritoneal Cancer 604
9.52 Prostate Cancer 606
9.53 Renal Cancer 611
9.54 Sarcoma (general) 615
9.55 Small Cell Lung Cancer 618
9.56 Soft Tissue Sarcoma 623
9.57 Solid Tumor 625
9.58 Squamous Cell Cancer 627
9.59 Synovial Sarcoma 628
9.60 T-cell Lymphoma 629
9.61 Testicular Cancer 630
9.62 Thyroid Cancer 631
9.63 Unspecified 636
9.64 Vaccine adjunct 643
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator 644
10.1 Competitive Fall-Out Assessment 644
10.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 646
10.3 Abbott 648
10.4 Abraxis BioScience 656
10.5 Acceleron Pharma 661
10.6 Access 664
10.7 ACT Biotech 667
10.8 Active Biotech 672
10.9 Adherex 675
10.10 Advanced Cancer Therapeutics 680
10.11 Advantagene 683
10.12 Advaxis 687
10.13 Advenchen 690
10.14 Aeterna Zentaris 693
10.15 Agennix 697
10.16 Aida Pharmaceuticals 700
10.17 Alnylam 703
10.18 Ambit Biosciences 706
10.19 Ambrilia Biopharma 710
10.20 Amgen 713
10.21 Amphora 719
10.22 Angiogen 723
10.23 Angiogenex 726
10.24 Angstrom Pharmaceuticals 729
10.25 Ansaris 733
10.26 Antisoma 737
10.27 Arana Therapeutics 740
10.28 Ariad 743
10.29 Arno Therapeutics 749
10.30 ArQule 752
10.31 Array BioPharma 756
10.32 Astex Therapeutics 759
10.33 AstraZeneca 762
10.34 Attenuon 768
10.35 Austrianova 773
10.36 Bayer 776
10.37 BioAlliance Pharma 781
10.38 BioAxone 784
10.39 Biocompatibles 787
10.40 Boehringer Ingelheim 791
10.41 Bolder BioTechnology 795
10.42 Bristol-Myers Squibb 799
10.43 CDG Therapeutics 807
10.44 Celecure 810
10.45 Celgene 813
10.46 Cell Therapeutics 816
10.47 CellCeutix 819
10.48 Cellmid 822
10.49 Cephalon 825
10.50 ChemoCentryx 828
10.51 Chemokine Therapeutics 831
10.52 China Sky One Medical 834
10.53 Choongwae 837
10.54 Circadian Technologies 840
10.55 Cue Biotech 843
10.56 Curis 846
10.57 Cyclacel 849
10.58 Cytochroma 852
10.59 Deciphera Pharmaceuticals 855
10.60 Dendreon 859
10.61 Dyax 862
10.62 Eisai 865
10.63 Eli Lilly 871
10.64 Endocyte 879
10.65 EntreMed 882
10.66 Exelixis 890
10.67 ExonHit Therapeutics 897
10.68 Facet Biotech 901
10.69 Five Prime Therapeutics 904
10.70 GammaCan 907
10.71 Genmab 911
10.72 GlaxoSmithKline 917
10.73 GlycoGenesys 922
10.74 Green Cross 925
10.75 Hoffmann-La Roche 929
10.76 Hy BioPharma 936
10.77 Idera Pharmaceuticals 939
10.78 ImClone Systems 943
10.79 ImmunoGen 946
10.80 ImmuPharma 949
10.81 Introgen Therapeutics 952
10.82 Isis Pharmaceuticals 956
10.83 Johnson & Johnson 959
10.84 KAI Pharmaceuticals 965
10.85 Karus Therapeutics 968
10.86 Kirin Pharma 971
10.87 Kringle Pharma 974
10.88 Kyowa Hakko Kirin 977
10.89 Lee’s Pharmaceutical 981
10.90 Lorus Therapeutics 984
10.91 MAT Biopharma 987
10.92 MediGene 990
10.93 Merck & Co 994
10.94 Merck KGaA 997
10.95 Mersana Therapeutics 1001
10.96 MethylGene 1004
10.97 Micromet 1007
10.98 MolMed 1010
10.99 Morvus Technology 1013
10.100 NewSouth Innovations 1016
10.101 Non-industrial Sources 1019
10.102 Novartis 1022
10.103 Novelix 1037
10.104 Oasmia 1040
10.105 Onconova 1043
10.106 OncoTherapy Science 1046
10.107 Oncothyreon 1050
10.108 OSI Pharmaceuticals 1053
10.109 Oxford BioMedica 1058
10.110 OXiGENE 1061
10.111 Pepscan Therapeutics 1065
10.112 PepTx 1069
10.113 Peregrine Pharmaceuticals 1072
10.114 Pfizer 1076
10.115 Pharmacopeia 1089
10.116 Pharmacyclics 1092
10.117 PharmaMar 1095
10.118 Pharminox 1099
10.119 Philogen 1102
10.120 PhiloGene 1105
10.121 Pierre Fabre 1108
10.122 Progen 1112
10.123 Protein Sciences 1115
10.124 PTC Therapeutics 1118
10.125 Receptor BioLogix 1122
10.126 Regeneron 1126
10.127 Rexahn 1131
10.128 Rigel 1134
10.129 Sanofi-Aventis 1137
10.130 Santaris Pharma 1140
10.131 Scancell 1144
10.132 SciClone Pharmaceuticals 1147
10.133 Semafore Pharmaceuticals 1150
10.134 Simcere Pharmaceuticals 1153
10.135 Spear Therapeutics 1158
10.136 SRI International 1161
10.137 SuperGen 1164
10.138 Switch Pharma 1167
10.139 SynDevRx 1170
10.140 Tau Therapeutics 1173
10.141 ThromboGenics 1177
10.142 Tigris Pharmaceuticals 1180
10.143 ToolGen 1183
10.144 TopoTarget 1187
10.145 Tracon Pharmaceuticals 1190
10.146 UCB 1193
10.147 VBL Therapeutics 1198
10.148 Wilex 1201
10.149 Wyeth 1205
10.150 Xerion 1208
11 Disclaimer 1212
12 Drug Index 1213
13 Company Index 1221

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Angiogenesis Affecting Drugs in Oncology 306
Figure 2: The Drug-Target Interactions of Angiogenesis Affecting Cancer Drugs - Large Cluster 308
Figure 3: The Drug-Target Interactions of Angiogenesis Affecting Cancer Drugs - Smaller Clusters 309
Figure 4: Head-to-Head Targeting Interactions of Angiogenesis Affecting Cancer Drugs – Large Clusters 310
Figure 5: Head-to-Head Targeting Interactions of Angiogenesis Affecting Cancer Drugs – Smaller Clusters 311
Figure 6: Distribution of Compound Strategies among Cancer Drugs Affecting Angiogenesis 478
Figure 7: Primary Sub-cellular Localization of Drug Targets 479

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 6
Table 2: Breakdown of the Included Cancer Pipeline of Angiogenesis Affecting Drugs by Stage of Development 35
Table 3: Head to Head Target Competition among Angiogenesis Affecting Drugs in Cancer 35
Table 4: Overview of Drug Target Strategy Themes 40
Table 5: Terminally Ceased Targets of Cancer Drugs Affecting Angiogenesis 41
Table 6: Targets of Angiogenesis Affecting Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 294
Table 7: Identity of Cancer Drug Targets with Available Biological Structures 298
Table 8: Number of Target-Target Interactions among Targets of Cancer Drugs 302
Table 9: Available Protein Expression Profiles of Cancer Drug Targets 312
Table 10: Pathway Summary 318
Table 11: Drug Targets without any Identified Assigned Pathways 318
Table 12: Pathway Profiles According to BioCarta of Cancer Drug Targets 320
Table 13: Pathway Profiles According to KEGG of Cancer Drug Targets 339
Table 14: Pathway Profiles According to NetPath of Cancer Drug Targets 362
Table 15: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 367
Table 16: Top Competitive Target Strategies of Cancer Drugs Affecting Angiogenesis 368
Table 17: Target Strategies of Terminated Cancer Drugs Affecting Angiogenesis 370
Table 18: New and Unique Target Strategies of Registered to Marketed Cancer Drugs Affecting Angiogenesis 374
Table 19: The Competition Through Close Mechanistic Approximation Between Registered to Marketed Cancer Drugs Affecting Angiogenesis 375
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Cancer Drugs Affecting Angiogenesis 376
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Cancer Drugs Affecting Angiogenesis 378
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Cancer Drugs Affecting Angiogenesis 380
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Cancer Drugs Affecting Angiogenesis 383
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Cancer Drugs Affecting Angiogenesis 388
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Cancer Drugs Affecting Angiogenesis 392
Table 26: New and Unique Target Strategies in Preclinical Development of Cancer Drugs Affecting Angiogenesis 397
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Cancer Drugs Affecting Angiogenesis 399
Table 28: New and Unique Target Strategies in Unknown Developmental Stage of Cancer Drugs Affecting Angiogenesis 401
Table 29: The Competition Through Close Mechanistic Approximation Between Cancer Drugs Affecting Angiogenesis with No Developmental Data in Cancer 402
Table 30: The Progression, Maturity and Competitive Comparison of Target Strategies of Cancer Drugs Affecting Angiogenesis 404
Table 31: The Competition Through Close Mechanistic Approximation Among All Cancer Drugs Affecting Angiogenesis 427
Table 32: Overview of Compound Strategy Competition Among Drugs in Oncology Affecting Angiogenesis 439
Table 33: Overview of the Competitive Landscape of Small Molecule Drugs Affecting Angiogenesis in Cancer 441
Table 34: The Competition Through Close Mechanistic Approximation between Small Molecule Drugs Affecting Angiogenesis in Cancer 442
Table 35: Competitive Comparison of Target Strategies of Small Molecule Drugs Affecting Angiogenesis in Cancer 450
Table 36: Overview of the Competitive Landscape of Peptide Based Drugs Affecting Angiogenesis in Cancer 459
Table 37: The Competition Through Close Mechanistic Approximation between Peptide Based Drugs Affecting Angiogenesis in Cancer 460
Table 38: Competitive Comparison of Target Strategies of Peptide Based Drugs Affecting Angiogenesis in Cancer 460
Table 39: Overview of the Competitive Landscape of Protein Based Drugs Affecting Angiogenesis in Cancer 462
Table 40: The Competition Through Close Mechanistic Approximation between Protein Based Drugs Affecting Angiogenesis in Cancer 463
Table 41: Competitive Comparison of Target Strategies of Protein Based Drugs Affecting Angiogenesis in Cancer 463
Table 42: Overview of the Competitive Landscape of Antibody Based Drugs Affecting Angiogenesis in Cancer 465
Table 43: The Competition Through Close Mechanistic Approximation between Antibody Drugs Affecting Angiogenesis in Cancer 466
Table 44: Competitive Comparison of Target Strategies of Antibody Based Drugs Affecting Angiogenesis in Cancer 467
Table 45: Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs Affecting Angiogenesis in Cancer 470
Table 46: The Competition Through Close Mechanistic Approximation between Nucleic Acid Therapy Drugs Affecting Angiogenesis in Cancer 471
Table 47: Competitive Comparison of Target Strategies of Nucleic Acid Drugs Affecting Angiogenesis in Cancer 471
Table 48: Vectors in Gene Therapy 472
Table 49: Overview of the Competitive Landscape of Gene Therapy based Drugs Affecting Angiogenesis in Cancer 472
Table 50: The Competition Through Close Mechanistic Approximation between Gene Therapy Based Drugs Affecting Angiogenesis in Cancer 473
Table 51: Competitive Comparison of Target Profiles of Gene Therapy Based Drugs Affecting Angiogenesis in Cancer 474
Table 52:Overview of the Competitive Landscape of Reformulated Drugs Affecting Angiogenesis in Cancer 475
Table 53: The Competition Through Close Mechanistic Approximation between Reformulated Drugs Affecting Angiogenesis in Cancer 476
Table 54: Competitive Comparison of Target Strategies of Reformulated Drugs Affecting Angiogenesis in Cancer 477
Table 55: Compound Strategies based on Sub-Cellular Localization of Angiogenesis Affecting Drug Targets 479
Table 56 Competitive Summary by Cancer Indication of Angiogenesis Affecting Drugs 487
Table 57: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Lymphocytic Leukemia 489
Table 58: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Myelogenous Leukemia 490
Table 59: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 492
Table 60: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Adrenal Cancer 493
Table 61: The Competition through Close Mechanistic Approximation between Adrenal Cancer Drugs 494
Table 62: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of B-cell Lymphoma 495
Table 63: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Basal Cell Cancer 496
Table 64: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Biliary Cancer 497
Table 65: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bladder Cancer 498
Table 66: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 500
Table 67: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bone Cancer 501
Table 68: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Brain Cancer 502
Table 69: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 504
Table 70: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Breast Cancer 506
Table 71: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 511
Table 72: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cancer (general) 515
Table 73: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cancer Diagnosis 516
Table 74: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Carcinoid 517
Table 75: The Competition through Close Mechanistic Approximation between Carcinoid Drugs 518
Table 76: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cervical Cancer 519
Table 77: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chemotherapy-induced Alopecia 520
Table 78: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chemotherapy-induced Infection 520
Table 79: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Lymphocytic Leukemia 521
Table 80: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Myelogenous Leukemia 522
Table 81: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of CNS Cancer 524
Table 82: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Colorectal Cancer 525
Table 83: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 530
Table 84: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Endometrial Cancer 534
Table 85: The Competition through Close Mechanistic Approximation between Endometrial Cancer Drugs 535
Table 86: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fallopian Tube Cancer 536
Table 87: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs 537
Table 88: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fibro Sarcoma 538
Table 89: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Cancer (general) 539
Table 90: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 540
Table 91: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stomach Cancer 542
Table 92: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 544
Table 93: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stromal Cancer 545
Table 94: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs 546
Table 95: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Head and Neck Cancer 547
Table 96: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 549
Table 97: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Hodgkin’s Lymphoma 551
Table 98: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Kaposi’s Sarcoma 551
Table 99: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leiomyo Sarcoma 552
Table 100: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leukemia (general) 553
Table 101: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lipo Sarcoma 555
Table 102: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Liver Cancer 556
Table 103: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 559
Table 104: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lung Cancer (general) 561
Table 105: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lymphoma (general) 563
Table 106: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mast Cell Leukemia 565
Table 107: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Melanoma 566
Table 108: The Competition through Close Mechanistic Approximation between Melanoma Drugs 569
Table 109: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mesothelioma 571
Table 110: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs 572
Table 111: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myelodysplastic Syndrome 573
Table 112: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myeloma 575
Table 113: The Competition through Close Mechanistic Approximation between Myeloma Drugs 577
Table 114: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Nasopharyngeal Cancer 578
Table 115: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (general) 579
Table 116: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (pancreatic) 580
Table 117: The Competition through Close Mechanistic Approximation between Neuroendocrine Cancer (pancreatic) Drugs 581
Table 118: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of non-Hodgkin’s Lymphoma 582
Table 119: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Non-Small Cell Lung Cancer 584
Table 120: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 588
Table 121: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oesophageal Cancer 592
Table 122: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oral Cancer 594
Table 123: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Osteo Sarcoma 594
Table 124: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Ovarian Cancer 595
Table 125: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 598
Table 126: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Pancreatic Cancer 600
Table 127: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 602
Table 128: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Peritoneal Cancer 604
Table 129: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 605
Table 130: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Prostate Cancer 606
Table 131: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 609
Table 132: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Renal Cancer 611
Table 133: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 612
Table 134: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Sarcoma (general) 615
Table 135: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs 617
Table 136: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Small Cell Lung Cancer 618
Table 137: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 622
Table 138: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Soft Tissue Sarcoma 623
Table 139: The Competition through Close Mechanistic Approximation between Soft Tissue Sarcoma Drugs 624
Table 140: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Solid Tumor 625
Table 141: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs 626
Table 142: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Squamous Cell Cancer 627
Table 143: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Synovial Sarcoma 628
Table 144: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of T-cell Lymphoma 629
Table 145: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Testicular Cancer 630
Table 146: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Thyroid Cancer 631
Table 147: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs 633
Table 148: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Unspecified Cancer Indication 636
Table 149: The Competition through Close Mechanistic Approximation between Unspecified Cancer Drugs 640
Table 150: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Vaccine adjunct 643
Table 151: Example of a Competitive Fall-Out Table (Modified, Platelet glycoprotein 4 trageting drugs) 645
Table 152: Summary Table of Corporate Changes in the Competitive Landscape of Angiogenesis Affecting Drug Development in Oncology 646
Table 153: Abbott’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 648
Table 154: Abraxis BioScience’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 656
Table 155: Acceleron Pharma’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 661
Table 156: Access’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 664
Table 157: ACT Biotech’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 667
Table 158: Active Biotech’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 672
Table 159: Adherex’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 675
Table 160: Advanced Cancer Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 680
Table 161: Advantagene’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 683
Table 162: Advaxis’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 687
Table 163: Advenchen’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 690
Table 164: Aeterna Zentaris’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 693
Table 165: Agennix’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 697
Table 166: Aida Pharmaceuticals’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 700
Table 167: Alnylam’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 703
Table 168: Ambit Biosciences’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 706
Table 169: Ambrilia Biopharma’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 710
Table 170: Amgen’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 713
Table 171: Amphora’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 719
Table 172: Angiogen’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 723
Table 173: Angiogenex’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 726
Table 174: Angstrom Pharmaceuticals’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 729
Table 175: Ansaris’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 733
Table 176: Antisoma’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 737
Table 177: Arana Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 740
Table 178: Ariad’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 743
Table 179: Arno Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 749
Table 180: ArQule’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 752
Table 181: Array BioPharma’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 756
Table 182: Astex Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 759
Table 183: AstraZeneca’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 762
Table 184: Attenuon’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 768
Table 185: Austrianova’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 773
Table 186: Bayer’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 776
Table 187: BioAlliance Pharma’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 781
Table 188: BioAxone’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 784
Table 189: Biocompatibles’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 787
Table 190: Boehringer Ingelheim’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 791
Table 191: Bolder BioTechnology’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 795
Table 192: Bristol-Myers Squibb’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 799
Table 193: CDG Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 807
Table 194: Celecure’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 810
Table 195: Celgene’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 813
Table 196: Cell Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 816
Table 197: CellCeutix’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 819
Table 198: Cellmid’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 822
Table 199: Cephalon’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 825
Table 200: ChemoCentryx’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 828
Table 201: Chemokine Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 831
Table 202: China Sky One Medical’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 834
Table 203: Choongwae’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 837
Table 204: Circadian Technologies’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 840
Table 205: Cue Biotech’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 843
Table 206: Curis’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 846
Table 207: Cyclacel’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 849
Table 208: Cytochroma’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 852
Table 209: Deciphera Pharmaceuticals’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 855
Table 210: Dendreon’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 859
Table 211: Dyax’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 862
Table 212: Eisai’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 865
Table 213: Eli Lilly’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 871
Table 214: Endocyte’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 879
Table 215: EntreMed’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 882
Table 216: Exelixis’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 890
Table 217: ExonHit Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 897
Table 218: Facet Biotech’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 901
Table 219: Five Prime Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 904
Table 220: GammaCan’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 907
Table 221: Genmab’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 911
Table 222: GlaxoSmithKline’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 917
Table 223: GlycoGenesys’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 922
Table 224: Green Cross’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 925
Table 225: Hoffmann-La Roche’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 929
Table 226: Hy BioPharma’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 936
Table 227: Idera Pharmaceuticals’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 939
Table 228: ImClone Systems’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 943
Table 229: ImmunoGen’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 946
Table 230: ImmuPharma’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 949
Table 231: Introgen Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 952
Table 232: Isis Pharmaceuticals’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 956
Table 233: Johnson & Johnson’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 959
Table 234: KAI Pharmaceuticals’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 965
Table 235: Karus Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 968
Table 236: Kirin Pharma’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 971
Table 237: Kringle Pharma’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 974
Table 238: Kyowa Hakko Kirin’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 977
Table 239: Lee’s Pharmaceutical’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 981
Table 240: Lorus Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 984
Table 241: MAT Biopharma’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 987
Table 242: MediGene’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 990
Table 243: Merck & Co’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 994
Table 244: Merck KGaA’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 997
Table 245: Mersana Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1001
Table 246: MethylGene’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1004
Table 247: Micromet’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1007
Table 248: MolMed’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1010
Table 249: Morvus Technology’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1013
Table 250: NewSouth Innovations’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1016
Table 251: Non-industrial Sources’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1019
Table 252: Novartis’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1022
Table 253: Novelix’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1037
Table 254: Oasmia’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1040
Table 255: Onconova’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1043
Table 256: OncoTherapy Science’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1046
Table 257: Oncothyreon’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1050
Table 258: OSI Pharmaceuticals’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1053
Table 259: Oxford BioMedica’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1058
Table 260: OXiGENE’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1061
Table 261: Pepscan Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1065
Table 262: PepTx’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1069
Table 263: Peregrine Pharmaceuticals’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1072
Table 264: Pfizer’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1076
Table 265: Pharmacopeia’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1089
Table 266: Pharmacyclics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1092
Table 267: PharmaMar’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1095
Table 268: Pharminox’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1099
Table 269: Philogen’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1102
Table 270: PhiloGene’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1105
Table 271: Pierre Fabre’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1108
Table 272: Progen’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1112
Table 273: Protein Sciences’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1115
Table 274: PTC Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1118
Table 275: Receptor BioLogix’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1122
Table 276: Regeneron’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1126
Table 277: Rexahn’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1131
Table 278: Rigel’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1134
Table 279: Sanofi-Aventis’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1137
Table 280: Santaris Pharma’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1140
Table 281: Scancell’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1144
Table 282: SciClone Pharmaceuticals’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1147
Table 283: Semafore Pharmaceuticals’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1150
Table 284: Simcere Pharmaceuticals’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1153
Table 285: Spear Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1158
Table 286: SRI International’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1161
Table 287: SuperGen’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1164
Table 288: Switch Pharma’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1167
Table 289: SynDevRx’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1170
Table 290: Tau Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1173
Table 291: ThromboGenics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1177
Table 292: Tigris Pharmaceuticals’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1180
Table 293: ToolGen’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1183
Table 294: TopoTarget’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1187
Table 295: Tracon Pharmaceuticals’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1190
Table 296: UCB’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1193
Table 297: VBL Therapeutics’ Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1198
Table 298: Wilex’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1201
Table 299: Wyeth’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1205
Table 300: Xerion’s Included Angiogenesis Targeting Drug Pipeline in Oncology and Competitive Fall-Out 1208

This report includes 148 investigators plus their collaborators:
Abbott
Abraxis BioScience
Acceleron Pharma
Access
ACT Biotech
Active Biotech
Adherex
Advanced Cancer Therapeutics
Advantagene
Advaxis
Advenchen
Aeterna Zentaris
Agennix
Aida Pharmaceuticals
Alnylam
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
Arana Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
Bayer
BioAlliance Pharma
BioAxone
Biocompatibles
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
CDG Therapeutics
Celecure
Celgene
Cell Therapeutics
CellCeutix
Cellmid
Cephalon
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
Cue Biotech
Curis
Cyclacel
Cytochroma
Deciphera Pharmaceuticals
Dendreon
Dyax
Eisai
Eli Lilly
Endocyte
EntreMed
Exelixis
ExonHit Therapeutics
Facet Biotech
Five Prime Therapeutics
GammaCan
Genmab
GlaxoSmithKline
GlycoGenesys
Green Cross
Hoffmann-La Roche
Hy BioPharma
Idera Pharmaceuticals
ImClone Systems
ImmunoGen
ImmuPharma
Introgen Therapeutics
Isis Pharmaceuticals
Johnson & Johnson
KAI Pharmaceuticals
Karus Therapeutics
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Lorus Therapeutics
MAT Biopharma
MediGene
Merck & Co
Merck KGaA
Mersana Therapeutics
MethylGene
Micromet
MolMed
Morvus Technology
NewSouth Innovations
Novartis
Novelix
Oasmia
Onconova
OncoTherapy Science
Oncothyreon
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaMar
Pharminox
Philogen
PhiloGene
Pierre Fabre
Progen
Protein Sciences
PTC Therapeutics
Receptor BioLogix
Regeneron
Rexahn
Rigel
Sanofi-Aventis
Santaris Pharma
Scancell
SciClone Pharmaceuticals
Semafore Pharmaceuticals
Simcere Pharmaceuticals
Spear Therapeutics
SRI International
SuperGen
Switch Pharma
SynDevRx
Tau Therapeutics
ThromboGenics
Tigris Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
UCB
VBL Therapeutics
Wilex
Wyeth
Xerion
This report includes 239 cancer drugs. From Ceased to Marketed.
A shortlist of drugs included are:
aflibercept
apatinib
ARQ-197
axitinib
bevacizumab
BIBF-1120
brivanib alaninate
cediranib
cilengitide
endostatin
enzastaurin hydrochloride
everolimus
fosbretabulin tromethamine
HBP-347
INGN-241
linifanib
midostaurin
motesanib diphosphate
OTS-102
patupilone
pazopanib hydrochloride
ramucirumab
ridaforolimus
sorafenib tosylate
sunitinib malate
talactoferrin alfa
thymalfasin
tipifarnib
vandetanib
XL-184

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline.
    To find out more about Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
This report comprises defined and up to date development strategies for 252 angiogenesis affecting drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications. Learn More


Competitive Outlook on Apoptosis in Oncology
Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Lung Cancer, Pancreatic Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Triple Analysis: Lung Cancer, Lymphoma and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Lymphoma and by the mechanism/target/effect of Angiogenesis. Learn More